Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
F Trillsch, S Mahner, F Hilpert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K H Baumann, A du Bois, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K Lindemann, G Kristensen, M R Mirza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Gynecologic Oncology
|
December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)
F T Roncolato, R L O'Connell, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
British Journal of Cancer
|
January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study
F Trillsch, S Mahner, E Vettorazzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
F Trillsch, S Mahner, L Woelber, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
F Trillsch, S Mahner, F Hilpert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K H Baumann, A du Bois, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K Lindemann, G Kristensen, M R Mirza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Gynecologic Oncology
|
December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)
F T Roncolato, R L O'Connell, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
British Journal of Cancer
|
January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study
F Trillsch, S Mahner, E Vettorazzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
F Trillsch, S Mahner, L Woelber, et al.
Page
of 4